Dongsung Pharm Cash Flow-to-Debt Ratio
Dongsung Pharm cash flow-to-debt ratio. Dongsung Pharm (002210) has a Cash Flow-to-Debt Ratio of 0.04x as of June 2025, meaning its operating cash flow of ₩4.20 Billion could theoretically repay 0% of its total liabilities (₩107.40 Billion) in one year. Check Dongsung Pharm (002210) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Dongsung Pharm (2008–2024)
Cash flow-to-debt ratio of Dongsung Pharm from 2008 to 2024. Historical debt coverage capacity for Dongsung Pharm across 13 annual periods. Check 002210 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Dongsung Pharm Cash Flow-to-Debt Ratio by Year (2008–2024)
Dongsung Pharm cash flow-to-debt ratio by year from 2008 to 2024. Year-by-year debt coverage analysis for Dongsung Pharm. For the full cash flow conversion analysis, see Dongsung Pharm cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.10x | ₩-9.94 Billion | ₩96.73 Billion | ▼ -80.0% |
| 2023 | -0.06x | ₩-4.29 Billion | ₩75.17 Billion | ▲ +4.5% |
| 2022 | -0.06x | ₩-3.88 Billion | ₩64.89 Billion | ▼ -26.4% |
| 2021 | -0.05x | ₩-2.75 Billion | ₩58.14 Billion | ▼ -166.9% |
| 2020 | 0.07x | ₩5.01 Billion | ₩70.77 Billion | ▲ +152.5% |
| 2019 | -0.13x | ₩-8.31 Billion | ₩61.63 Billion | ▼ -900.0% |
| 2018 | 0.02x | ₩1.39 Billion | ₩82.71 Billion | ▼ -43.9% |
| 2017 | 0.03x | ₩1.80 Billion | ₩59.91 Billion | ▲ +162.6% |
| 2016 | -0.05x | ₩-3.34 Billion | ₩69.77 Billion | ▼ -16.7% |
| 2011 | -0.04x | ₩-2.64 Billion | ₩64.38 Billion | ▼ -176.6% |
| 2010 | 0.05x | ₩3.68 Billion | ₩68.71 Billion | ▲ +164.0% |
| 2009 | -0.08x | ₩-5.02 Billion | ₩59.94 Billion | ▼ -1201.5% |
| 2008 | -0.01x | ₩-365.26 Million | ₩56.75 Billion | — |